Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Purchased by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. increased its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 3.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,939 shares of the company’s stock after purchasing an additional 578 shares during the period. Levin Capital Strategies L.P.’s holdings in Pulse Biosciences were worth $472,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Citigroup Inc. lifted its stake in shares of Pulse Biosciences by 297.1% in the 4th quarter. Citigroup Inc. now owns 2,696 shares of the company’s stock worth $64,000 after acquiring an additional 2,017 shares during the period. Bender Robert & Associates purchased a new position in shares of Pulse Biosciences in the 1st quarter valued at about $209,000. The Manufacturers Life Insurance Company purchased a new position in shares of Pulse Biosciences in the 4th quarter valued at about $220,000. Wolverine Trading LLC purchased a new position in shares of Pulse Biosciences in the 4th quarter valued at about $276,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Pulse Biosciences by 23.5% in the 4th quarter. New York State Common Retirement Fund now owns 12,100 shares of the company’s stock valued at $289,000 after purchasing an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 11.42% of the company’s stock.

PLSE has been the subject of several recent research reports. HC Wainwright raised their target price on shares of Pulse Biosciences from $40.00 to $46.00 and gave the company a “buy” rating in a report on Thursday, February 4th. Zacks Investment Research cut shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Maxim Group began coverage on shares of Pulse Biosciences in a research note on Wednesday, March 17th. They set a “buy” rating and a $40.00 price target on the stock.

Shares of PLSE stock opened at $17.45 on Monday. The stock has a market cap of $461.73 million, a price-to-earnings ratio of -7.69 and a beta of 1.88. Pulse Biosciences, Inc. has a fifty-two week low of $7.73 and a fifty-two week high of $45.82. The firm’s 50 day moving average price is $20.84 and its two-hundred day moving average price is $23.47.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Sunday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.19). On average, research analysts anticipate that Pulse Biosciences, Inc. will post -2.05 earnings per share for the current fiscal year.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology.

Further Reading: What are catch-up contributions?

Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc. (NASDAQ:PLSE).

Institutional Ownership by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.